Combination Therapy for RNA Virus Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments for COVID-19 caused by SARS-CoV-2, particularly due to the lack of therapeutically effective treatments and the moderate potency of existing antiviral drugs like remdesivir.
Innovation Solution
Administering combined effective amounts of an RNA-dependent RNA polymerase inhibitor, such as remdesivir, with a second therapeutic agent, including HCV inhibitors, B-Raf inhibitors, proton pump inhibitors, and other agents, to synergistically treat RNA virus infections, reducing symptom severity and viral load.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If remdesivir is used as monotherapy for SARS-CoV-2 infection, then the treatment can be administered simply, but the potency is moderate and treatment efficacy is limited
Solution Approach 1:
The patent combines remdesivir with a second therapeutic agent (such as HCV inhibitors, B-Raf inhibitors, proton pump inhibitors, or other agents listed in the specification) to create a combination therapy regimen. This merging of two separate treatments addresses the moderate potency of remdesivir alone by adding synergistic effects, thereby improving overall treatment efficacy while accepting increased regimen complexity as a trade-off
2Reliability
If the dosage of remdesivir is increased to improve treatment efficacy, then the therapeutic effect may be enhanced, but the risk of side effects and toxicity increases
Solution Approach 1:
The patent changes the dosing parameters by administering remdesivir in combination with a second therapeutic agent. This parameter change allows for achieving enhanced therapeutic effect through synergistic interaction between the two agents, thereby potentially using lower doses of remdesivir compared to monotherapy, which reduces the risk of side effects and toxicity while maintaining or improving efficacy
3Reliability
If a combination therapy with multiple agents is used, then the treatment efficacy is enhanced with synergistic effects, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent merges remdesivir with a second therapeutic agent from specific categories (HCV inhibitors, B-Raf inhibitors, proton pump inhibitors, or other listed agents) to achieve synergistic effects that enhance treatment efficacy. The combination is designed to target different aspects of viral infection or host response, creating a more robust therapeutic effect while managing the complexity through selective pairing of agents with complementary mechanisms of action
Data Source
AI summary
The present disclosure provides methods of treating an RNA virus infection. The methods comprise administering combined effective amounts of an RNA-dependent RNA polymerase inhibitor, such as remdesivir, and a second therapeutic agent for treating infection with an RNA virus.